newsfilter
← Latest News
GlobeNewswire·

NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23

  • NeOnc Technologies Holdings, Inc. announced the FDA rescheduled its End-of-Phase 1 Type B meeting for oral NEO212 from November 17, 2026, to Monday, November 23, 2026.
  • The company intends to seek FDA feedback on NEO212's Phase 2 clinical development program, including patient population, trial design, endpoints, dose selection, and potential regulatory pathways.
  • Phase 1 dose escalation for the NEO212-01 trial was discontinued following dose-limiting toxicity at 810 mg, leading to the selection of 610 mg as the recommended Phase 2 dose.
  • FDA authorization to proceed with Phase 2a and Phase 2b portions of the NEO212-01 trial was granted in September 2025.
  • Encouraging Phase 1 clinical activity included a partial response with 60% tumor reduction lasting 21 months in a glioblastoma patient, and stable disease lasting 16 months in a lung cancer patient with brain metastases.
  • Management anticipates hosting an investor webinar after the issuance and receipt of the FDA's official meeting minutes to discuss feedback and next steps.
  • NEO212 is an investigational oral conjugate of temozolomide and NEO100 being studied for CNS cancers, with clinical efficacy and safety not yet established.
Company
NeOnc Technologies Holdings, Inc.
Keywords
Nasdaq:NTHI, NeOnc Technologies Holdings, Inc., FDA, biotechnology, NeOnc, Type B Meeting, NEO212, blood brain barrier, brain tumors, Cancer, central nervous system cancers, clinical, CNS